• > NICE Guidance
DHSSPS is an Accredited Investor in People Organisation
Home  > CMO / Public Health  > Safety, Quality and Standards  > Guidance  > NICE Guidance 

Safety, Quality and Standards

NICE (The National Institute for Health and Clinical Excellence)

NICE is a Special Health Authority tasked with providing guidance on current best practice in health treatment and care, including public health, to the NHS in England and Wales.  The Department has a formal link with the Institute under which all NICE guidance, published from 1 July 2006, is reviewed locally for its applicability to Northern Ireland and, where found to be applicable, is endorsed by the Department for implementation in the HPSS.  Further details are available in the circulars below.

NICE Guidance

NICE Guidance endorsed to date is set out below:
  • National Institute for Health and Clinical Excellence (NICE)Technology Appraisal No 139 – Continuous Positive Airway Pressure (CPAP) for the Treatment of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS)
  • National Institute for Health and Clinical Excellence (NICE) NICE Technology Appraisal No137 – Rituximab for the Treatment of Relapsed or Refractory Stage iii or Stage iv Follicular Non-Hodgkin’s Lymphoma
  • National Institute for Health and Clinical Excellence (NICE) NICE Technology Appraisal No 156 - Pregnancy - Routine Antenatal Anti-D Prophylaxis for Women who are Rhesus D Negative
  • National Institute for Health and Clinical Excellence (NICE) NICE Technology Appraisal No 155 - Pegaptanib and Ranibizumab for Age-related Macular Degeneration
  • National Institute for Health and Clinical Excellence (NICE) NICE Clinical Guideline No 64 - Antibiotic Prophylaxis Against Infective Endocarditis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA 131 Inhaled Corticosteroids for the treatment of chronic Asthma in Children Under the Age of 12 Years
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA 130 Adalimumab, Etanercept and Infliximab for the treatment of Rheumatoid Arthritis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal 128 - Stapled Haemorroidopexy for the treatment of Haemorrhoids
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 102 Parent-Training/Education Programmes in the management of Children with conduct Disorders
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 135 - Pemetrexed Disodium for the Treatment of Malignant Pleural Mesothelioma
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 122 - Alteplase for the Treatment of Acute Ischaemic Stroke
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 117 - Cinacalcet for the Treatment Secondary Hyperparathyroidism in Patients with End-Stage Renal Disease on Maintenance Dialysis
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 119 - Fludarabine Monotherapy for the First-line Treatment of Chronic Lymphocytic Leukaemia (CLL)
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal No TA 106 - Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
  • National Institute for Health and Clinical Excellence (NICE) No CG 38 - Bipolar Disorder - The Management of bipolar disorder in adults, children and adolescents, in Primary and Secondary care.
  • National Institute for Health and Clinical Excellence (NICE) No CG 35 - Parkinson's Disease - Diagnosis and Management in Primary and Secondary Care
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - The Management of Urinary Incontinence in Women
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Colorectal Cancer - Bevacizumab and Cetuximab
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Drug Misuse - Methadone and Buprenorphine
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Inhaled Insulin for the Treatment of Diabetes Mellitus Types 1 & 2
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HSC - Psoriasis – Efalizumab and Etanercept
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Prostate Cancer (Hormone Refractory) Docetaxal
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Colorectal Cancer - Laparoscopic Surgery
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Breast Cancer (early) Trastuzumab (Herceptin)
  • National Institute for Health and Clinical Excellence (NICE) Technology Appraisal for Implementation in the HPSS - Psoriatic Arthritis - Etanercept & Infliximab
Quick Links
Download Free Adobe Acrobat Reader - Links to an External Site